ONO L 0.03mg/kg/min 1min 0.01mg/kg/min 10min M 0.03mg/kg/min 1min 0.02mg/kg/min 10min H 0.06mg/kg/min 1min 0.04mg/kg/min 10min 3 1) LSD p=0.000
|
|
- さや いなくら
- 5 years ago
- Views:
Transcription
1 ONO L 0.03mg/kg/min1min0.01mg/kg/min10minM 0.03mg/kg/min1min0.02mg/kg/min 10minH 0.06mg/kg/min1min0.04mg/kg/min10min 3 1) LSD p=0.0001) 30 2) FACCFSVcfc LVESWS EDA DT MH LSD p<0.05)peak E peak A E/A 3) LMH RR LSD L p=0.0021mh p=0.0001)pq QRS QT ST 4) ONO-1101 ONO-1101 ONO-1101 ONO
2 100 / Hypovolemia 4 160/95 mmhgwho ONO ) 20 ONO mg/ mg/kg/min 0.01mg/kg/min mg/ kg/min 0.02mg/kg/min 0.06mg/kg/min 0.04mg/kg/min
3 1 50mg 5mL 1 ml/min mg 5mL 10 ml/min nifedipinenicardipinenilvadipine Ca FAC( )CFS( )Vcfc( )EDA( )LVESWS( )peak E( E )peak A( A )E/A( E / A ) DT(E ) 502
4 % 2 20% 3 20% 4 10% % 3 (20% 4 10% 5 10%
5 (RR PQ QRS QT ST ) (FAC, CFS, Vcfc) (LVESWS) (peak E, peak A, ) (LSD) 5% 1) T.Ryan, A.Timoney, A.J.Cunningham : Use of transoesophageal echocardiography to manage beta-adrenoceptor block and assess left ventricular function In a patient with pheaeochromocytoma. Br.J.Anaeth. 70: , ) Christopher J.O., David M.R., Jeffrer S.S. et al. : The effect of esmolol pretreatment on the incidence of regional wall motion abnomrmalities during electroconvulsive therapy. Anaeth.Analg. 82: ,
6 0.03mg/kg/min mg/kg/min L )0.06mg/kg/min mg/kg/min M )0.125mg/kg/min mg/kg/min H ) %90.7% ONO-1101 L M H /95mmHg / 4 85 / 505
7 506
8 LSD p=0.0001)h 30 LSD 30 p= p=0.0012) ANOVA : p= E1 507
9 85.7% 508
10 (mmhg) ANOVA : N.S. (FAC) (CFS) (Vcfc) (EDA) (LVESWS) peak E (peak E)peak A (peak A)peak E /peak A (E/A) E (DT) M H LSD p<0.05) DT 30 FAC (%) CFS (%) Vcfc (circ/sec) (ANOVA) 509
11 EDA (cm 2 ) LVESWS (g/cm 2 ) (ANOVA) peak E (cm/sec) peak A (cm/sec) E/A DT (cm/sec) (ANOVA) RR LSD L p=0.0021mh p=0.0001)pq QRS QT ST 510
12 ONO-1101 DT 1 DT 30 ONO ) Mantero A, Gentile F, Gualtierotti C, et al. : Left ventricular diastolic parameters in 288 normal subjects from 20 to 80 years old. Eur Heart J 16:94-105,
13 ONO %(17/28) ) mg/kg/min ONO-1101 ONO mg/kg/min mg/kg/min 10 ONO ASAAmerican Society of Anesthesiologist
14 ONO ONO mg/ 0.125mg/kg/min1 0.04mg/kg/min mg/kg/min 1 50mg 5mL 1 ml/min mg 5mL 10 ml/min nifedipinenicardipinenilvadipine Ca
15 / / 115 / / 130 / /
16 (RR PQ QRS QT ST ) t 5% mg/kg/min mg/kg/min 10 L ) 0.06mg/kg/min mg/kg/min 10 M ) 0.125mg/kg/min mg/kg/min 10 H )3 3 H 0.04mg/kg/min mg/kg/min 515
17 30 ECG
18 / 60.7% 517
19 / / / / 31.0%(9/29) 518
20 / GPT 519
21 72.4% 520
22 53.6% mmHg mmHg mmHg mmHg mmHg mmHg mmHg mmHg RPP bpmmmHg bpmmmHg bpmmmHg bpmmmHg 521
23 ONO-1101 ONO ng/mL ng/mL 0.04mg/kg/min 1000ng/mL ng/mL pg/mL pg/mL pg/mL pg/mL paired t p= p= p=0.0001) pg/mL pg/mL pg/mL paired t p= p=0.0213) pg/mL / / 50 / /) / mmhg mmHg
24 ONO % ONO % 523
25 RR QT paired t p=0.0001)qrs QTc PQ 524
26 ONO /51mmHg /74mmHg 8 76/53mmHg 9 60 /
27 526
28 1 ONO / 60.7% 1 RPP bpm mmhg bpmmmHg ONO
1 1)
--------------------------------------------------------- 1 -------------------------------------------------------------------------- 1 -------------------------------------------------------------------------------------
More information福島県2012-初校.indd
2012 FUKUSHIMA http://www.kairyudo.co.jp/ 2 4 5 1 2 3 2 3 20092008 kg cm 1500m 1000m 20m 50 m cm m 12 25.08 6.15 24.66 6.17 22.03 4.23 22.08 4.45 13 30.32 6.40 30.10 6.99 24.37 4.17 23.97 4.48 14 35.10
More information2 2000 3 31 209 5.6.2 2000 3 31 209211 52
10 45m 700900mm 400600mm 1m 3060 12m 11.5cm 40cm 900mm 2000 5 71 2.4-1 2000 3 31 237245 2000 5 7172 51 2 2000 3 31 209 5.6.2 2000 3 31 209211 52 6 1 1 900mm 1 2 3 53 2000 3 31 234 5.6.34 2000 3 31 232234
More information「諸雑公文書」整理の中間報告
30 10 3 from to 10 from to ( ) ( ) 20 20 20 20 20 35 8 39 11 41 10 41 9 41 7 43 13 41 11 42 7 42 11 41 7 42 10 4 4 8 4 30 10 ( ) ( ) 17 23 5 11 5 8 8 11 11 13 14 15 16 17 121 767 1,225 2.9 18.7 29.8 3.9
More information2
1 2 3 4 5 6 7 8 9 10 11 12 13 14 10 6 15 7 13 7 14 13 31 13 13 9 30 13 10 14 13 10 25 13 11 29 13 11 30 14 111 14 223 14 2 23 3 17 14 3 17 14 3 21 14 3 26 13 11 29 5 2 2 14 1 11 1 3 28 1 3 14 2 28 1 28
More informationMETs WPW QT LQTS 9Brugada 0 METs 30 Circulation Journal Vol. 67, Suppl. IV,
2002002 Guidelines for Exercise Eligibility at Schools, Work-Sites, and Sports in Patients with Heart Diseases (JCS 2003) JR 2 3 2 3 2 2 3 2 2 3 Circulation Journal Vol. 67, Suppl. IV, 2003 309 2002002
More information3 4 6 7 8 9 10 12 14 2 3
3 4 6 7 8 9 10 12 14 2 3 POINT 4 5 3053 1323 4 7 6 1 1 4 7 Yamada N. et al : Int J Cardiol. 98, 409-411, 2005 6 7 POINT 0 20 40 60 80 100 60 80 Ota M. et al: Heart Vessels. 17, 7-11,2002 40 60 20 50 15
More information1 2
1 2 4 3 5 6 8 7 9 10 12 11 0120-889-376 r 14 13 16 15 0120-0889-24 17 18 19 0120-8740-16 20 22 21 24 23 26 25 28 27 30 29 32 31 34 33 36 35 38 37 40 39 42 41 44 43 46 45 48 47 50 49 52 51 54 53 56 55 58
More information3 5 6 7 7 8 9 5 7 9 4 5 6 6 7 8 8 8 9 9 3 3 3 3 8 46 4 49 57 43 65 6 7 7 948 97 974 98 99 993 996 998 999 999 4 749 7 77 44 77 55 3 36 5 5 4 48 7 a s d f g h a s d f g h a s d f g h a s d f g h j 83 83
More information:,, : - 7 -
31 ~ ~ - 6 - :,, : - 7 - (),,,,,,; ~ ~ *1 *2 6,,,~,,~ - 8-32 ,, ( );( ),,,,,, ~ ~ ~,,,, (),,,,, - 9 - 33 ~*~ ~~ ~, ~ ~ ~ ~ ~, ~~,,,, - 10 - BCG () g ) BCG BCG,, 34 ,,,, (),,,,,,,,,,,,,, () ( 3 90 [7 6
More information4.4 R............................................. 13 4.5 q.............................................. 13 4.6 s....................................
2014.04.12 2014.12.12 1 3 2 4 2.1............................................ 4 2.2 Einthoven triangle........................................ 4 2.3............................................ 4 2.4.............................................
More informationBUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI
20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old
More informationMicrosoft Word - 表紙資料2-4
(1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)
More informationP1-1 P1-2 P1-3 P1-4 P1-5 P1-6 P3-1 P3-2 P3-3 P3-4 P3-5 P3-6 P5-1 P5-2 P5-3 P5-4 P5-5 P5-6 P7-1 P7-2 P7-3 P7-4 P7-5 P7-6 P9-1 P9-2 P9-3 P9-4 P9-5 P9-6 P11-1 P11-2 P11-3 P11-4 P13-1 P13-2 P13-3 P13-4 P13-5
More informationMH MH 9.50 8.50 9.40 8.40 9.30 9.20 8.30 9.10 9.00 8.20 8.90 8.80 8.10 8.70 8.60 8.00 8.50 7.90 8.40 8.30 7.80 8.20 8.10 7.70 8.00 7.60 7.90 7.80 7.50 7.70 7.60 7.40 1 7.50 7.40 7.30 2 7.30 7.20 7.20
More informationSymposium 46 I I II II III III 1 12 54/ narrow QRS tachycardia 139/ P V1 HIS 5 6 HIS 3 4 HIS 1 2 CS 9 10 CS 7 8 CS 5 6 CS 3 4 CS 1 2 RV 3 4 RV 1 2 100
Symposium 46 Inappropriate Sinus Tachycardia1 inappropriate sinus tachycardiaistp 100/ 1 IST 2 IST IST atrio ventricular nodal reentrant tachycardiavnrt IST 1 26 2011 24 2013 2013 7 54/ 1 narrow QRS 139/aVFP1
More information200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3
More informationuntitled
-- -- -3- % % % 6% % % 9 66 95 96 35 9 6 6 9 9 5 77 6 6 5 3 9 5 9 9 55 6 5 9 5 59 () 3 5 6 7 5 7 5 5 6 6 7 77 69 39 3 6 3 7 % % % 6% % % (: ) 6 65 79 7 3 36 33 9 9 5 6 7 3 5 3 -- 3 5 6 76 7 77 3 9 6 5
More informationuntitled
NO. 2007 10 10 34 10 10 0570-058-669 http://www.i-nouryoku.com/index.html (40 ) () 1 NO. 2007 10 10 2.2 2.2 130 70 20 80 30 () () 9 10 () 78 8 9 () 2 NO. 2007 10 10 4 7 3 NO. 2007 10 10 40 20 50 2 4 NO.
More information098青沼班DGfinal修正0506.indd
1 2011 Brugada QT 2005 2006 2007 Brugada Brugada 20 QT 70 2007 Brugada ICD ICD 5 2 QT Brugada 2012 QT QT QT Brugada Brugada 5 AHA/ACC ESC I II III A B C I II IIa IIb III A B C QT long QT syndrome LQTS
More informationmg 8 mg X Cr 9.84 mg/ dl K 1.5 meq/l CK 24,570 U/L Mb 79,530 ng/ml Mb 230,000 ng/ ml AKI 2 IHD IHD 4 IHD
31 1 15 20 2016 15 3 65 5 mg 8 mg 10 15 201X 7 1 11 15 Cr 9.84 mg/ dl K 1.5 meq/l CK 24,570 U/L Mb 79,530 ng/ml Mb 230,000 ng/ ml AKI 2 IHD IHD 4 IHD AKI HD 2004 48 Acute Kidney Injury AKI 48 Cr 0.3 mg/dl
More information, 360ml P , 360ml P , 360ml P , 40, 720ml P , 14, 2
3-1 3-1 20 2600, 20, 360ml P.35 3-2 3-2 16 2700, 16, 280ml P.35 3-3 3-3 20 2600, 20, 360ml P.35 3-4 3-4 19 2600, 19, 340ml P.35 3-5 3-5 20 2900, 20, 360ml P.35 3-6 3-6 18 3000, 18, 320ml P.35 3-7 3-7 18
More informationml ml ml mg ml ml mm mm mm mm mm mm mm mm mm mm mm ml mmhg mmhg ml Acetylcholine ml mg mm mm mm mm mm mm ope ++ Uribe Davis S H S S : : : : : : : : : G
More information1 z q w e r t y x c q w 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 R R 32 33 34 35 36 MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR
More information1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)
2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)
More information秋田県2012-初校.indd
http://www.kairyudo.co.jp/ 2012 AKITA 2 3 4 10 15 1 2 3 2 cm 110.7 111.6 109.8 110.6 5 kg 19.0 19.5 18.6 19.1 cm 61.9 62.2 61.5 61.6 cm 116.7 117.8 115.8 116.8 6 kg 21.4 22.5 21.0 21.9 cm 64.9 65.4 64.5
More information0.01mg/ ç 0.01 mg/ ç 0.01 mg/ ç 0.01 mg/ ç 0.05 mg/ ç 0.05 mg/ ç 0.01 mg/ ç 0.01 mg/ ç 0.0005mg/ ç 0.0005mg/ ç 0.02 mg/ ç 0.02 mg/ ç 0.002 mg/ ç 0.002 mg/ ç 0.004 mg/ ç 0.004 mg/ ç 0.02 mg/ ç 0.02 mg/
More information02.O...r.A..
8 300ha k (m 3 / / ) (0 2 ) 0405 135 270 2 12 0540 162 351 12 24 0810 216 486 500kg 135 459 127 1987 (m 3 / / ) 0566 2266 5947 9 18kg 0057 0425 1019 18 45 0142 0566 1358 45 675 0198 0708 2038 675 945 0283
More information2
a DEF MNO WXYZ ABC JKL TUV GHI PQRS 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 2 3 RUN VB-F050 ALARM a 1 2 4 3 5 6 4 7 5 8 9 10 6 11 12 13 7 14 15 16 18 17 8 9 1 10 1 11 1 12 1 13 1 14 1 15 1 16 VB-F050
More informationESL ()-methyl 3-{4-[2-hydroxy-3-(isopropylamino)pro poxy]phenyl} propanoate monohydrochloride H 3 C O O JAN( ) JAN( )esmolol hydrochloride r-inn( )esm
1 186 186 (1) - 192 (2) (ISAintrinsic sympathomimetic activity) 199 (3) ( MSAmembrane stabilizing activity) 2 (4) 21 (5) 212 (6) 216 (7) 219 (8) 224 (9) (ASL-8123) - 229 (1) d-esl l-esl - 231 2 235 235
More information8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio
7-14 2010 1 1 1 2 1 1 1 2 Fontaine II ASO61 3 API ASO ASO ASO API API KKKKKKKKKK ASO Fontaine II API Received April 14, 2009; Accepted July 16, 2009 I arteriosclerosis obliterans: ASO ASO 50 70 1,2 Fontaine
More information岩手県2012-初校.indd
http://www.kairyudo.co.jp/ 2012 IWATE 2 3 4 16 1 2 3 2 14 165.6 165.2 55.2 54.3 88.6 88.1 cm kg cm 13 160.1 159.7 50.1 49.1 85.1 84.9 12 153.5 152.5 46.3 44.2 81.9 81.3 13 155.4 154.9 48.9 47.3 84.2 83.7
More information(1) θ a = 5(cm) θ c = 4(cm) b = 3(cm) (2) ABC A A BC AD 10cm BC B D C 99 (1) A B 10m O AOB 37 sin 37 = cos 37 = tan 37
4. 98 () θ a = 5(cm) θ c = 4(cm) b = (cm) () D 0cm 0 60 D 99 () 0m O O 7 sin 7 = 0.60 cos 7 = 0.799 tan 7 = 0.754 () xkm km R km 00 () θ cos θ = sin θ = () θ sin θ = 4 tan θ = () 0 < x < 90 tan x = 4 sin
More information:30 100m 4 3 (2 ) 5 (3 ) 7 (1 ) 16 OB OG m 200m (2 ) m (1 ) 4 (3 ) 2m m 10:35 100m 3 (3 ) 5 OB OG (1
2003 10 1 1 1.1............ 1 1.2............ 2 1.3.......... 2 1.4.............. 2 1.5.............. 7 1.6.............. 10 2 11 100m,200m 200m 21 2.1............ 11 2m A 1 2.2.... 11 1500m 3 1 14m15
More information20mg CTD 2.4 2.4 2.4... 5 2.4.1... 5 2.4.2... 7 2.4.3... 10 2.4.4... 13 2.4.5... 18 2.4.6... 20 3 2.4 2.4 2.4.1 JNS002 ( HSPC) N-(Carbonyl-methoxypolyethylene glycol 2000)-1,2- distearoyl-sn-glycero-3-phosphoethanolamine
More information青森県2012-初校.indd
http://www.kairyudo.co.jp/ 2012 AOMORI 2 3 9 16 1 2 3 2010 6 128.9 128.2 128.7 8 9 31.7 30.0 31.7 30.0 22.5 21.4 21.9 21.0 117.2 116.7 116.3 115.8 65.1 64.9 64.7 64.5 7 25.3 24.0 24.9 23.5 123.1 122.5
More information2002 (1) (2) (3) (4) (5) (1) (2) (3) (4) (5) (1) (2) (3) (4) (5) (6) (7) (8) (1) (2) (3) (4) (1) (2) (3) (4) (5) (6) (7) (8) No 2,500 3 200 200 200 200 200 50 200 No, 3 1 2 00 No 2,500 200 7 2,000 7
More information180 30 30 180 180 181 (3)(4) (3)(4)(2) 60 180 (1) (2) 20 (3)
12 12 72 (1) (2) (3) 12 (1) (2) (3) (1) (2) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (1) (2) 180 30 30 180 180 181 (3)(4) (3)(4)(2) 60 180 (1) (2) 20 (3) 30 16 (1) 31 (2) 31 (3) (1) (2) (3) (4) 30
More informationuntitled
1....1 2....2 2.1...2 2.2...2 3....14 3.1...14 3.2...14 4....15 4.1...15 4.2...18 4.3...21 4.4...23 4.5...26 5....27 5.1...27 5.2...35 5.3...54 5.4...64 5.5...75 6....79 6.1...79 6.2...85 6.3...94 6.4...
More information113 120cm 1120cm 3 10cm 900 500+240 10 1 2 3 5 4 5 3 8 6 3 8 6 7 6 8 4 4 4 4 23 23 5 5 7
More informationuntitled
21 14 487 2,322 2 7 48 4 15 ( 27) 14 3(1867) 3 () 1 2 3 ( 901923 ) 5 (1536) 3 4 5 6 7 8 ( ) () () 9 10 21 11 12 13 14 16 17 18 20 1 19 20 21 22 23 21 22 24 25 26 27 28 22 5 29 30cm 7.5m 1865 3 1820 5
More information1948 1907 4024 1925 14 19281929 30 111931 4 3 15 4 16 3 15 4 161933 813 1935 12 17 11 17 1938 1945 2010 14 221 1945 10 1946 11 1947 1048 1947 1949 24
15 4 16 1988 63 28 19314 29 3 15 4 16 19283 15294 16 1930 113132 3 15 4 16 33 13 35 12 3 15 4 16 1945 10 10 10 10 40 1948 1907 4024 1925 14 19281929 30 111931 4 3 15 4 16 3 15 4 161933 813 1935 12 17 11
More information裁定審議会における裁定の概要 (平成23年度)
23 23 23 4 24 3 10 11 12 13 14 () 1 23 7 21 23 12 14 (19 ) 30 1.876% 60 8 24 19 78 27 1 (10) 37 (3) 2 22 9 21 23 5 9 21 12 1 22 2 27 89 10 11 6 A B 3 21 12 1 12 10 10 12 5 1 9 1 2 61 ( 21 10 1 11 30 )
More information<91E6825289F1938C966B95FA8ECB90FC88E397C38B5A8F708A778F7091E589EF8EC08D7388CF88F5837D836A83858341838B566572312E696E6464>
More information
Microsoft Word - 入居のしおり.doc
1 1 2 2 2 3 2 4 3 5 3 6 3 7 3 8 4 1 7 2 7 3 7 4 8 5 9 6 9 7 10 8 10 9 11 10 11 11 11 12 12 13 13 1 14 2 17 3 18 4 19 5 20 6 22 (1) 24 (2) 24 (3) 24 (4) 24 (5) 24 (6) 25 (7) 25 (8) 25 (9) 25 1 29 (1) 29
More information和県監査H15港湾.PDF
...1...1...1...1...1...1...1...1...2...2...2...3...3...3...5...5...10...11...12...13...13...13...14...14...14...14...14...14...15...15...15...15...15 ...16...17 14...17...18...18...19...21...23 2...25...27...27...28...28...28
More information( )
( ) () () 3 cm cm cm cm cm cm 1000 1500 50 500 1000 1000 1500 1000 10 50 300 1000 2000 1000 1500 50 10 1000 2000 300 50 1000 2000 1000 1500 50 10 1000 2000 300 30 10 300 1000 2000 1000 1500 1000
More information-26-
-25- -26- -27- -28- -29- -30- -31- -32- -33- -34- -35- -36- -37- -38- cm -39- -40- 1 2 3 4 4 3 2 1 5 5-41- -42- -43- -44- -45- -46- -47- -48- -49- -50- cm -51- -52- -53- -54- -55- -56- -57- -58- -59- -60-
More information-1- 4 1 2 4-2- -- 2 2 cm 0 80cm 2 80cm 80cm 80cm 50cm 80cm 50cm 6 80cm 100 50 50 cm 10 6 4 50cm 4 4 50cm -4- -5- cm 50cm 4 4 4 50cm 50cm 4 80cm 50cm 80cm 50cm 6 cm -6- 20 250cm 1 2 1 4 0cm 60cm cm cm 1
More informationuntitled
() () () () () ( ) () ( ) () ( ) () 2 () () 2 () () ( ) () () () 2 () () 2 3 ( ) () ( ) 2 3 4 () () 2 3 4 () () ( )( ) ( ) 2 ( ) 3 () () 2 3 () () 2 3 () () () () () () () () (( ) ( ) (( ))( )( ) ) 2 3
More information河川砂防技術基準・基本計画編.PDF
4 1 1 1 1 1 2 1 2.1 1 2.2 2 2.3 2 2.4 2 3 2 4 3 2 4 1 4 1.1 4 1.2 4 2 4 2.1 4 2.2 4 2.3 5 2.4 5 2.5 5 2.5.1 5 2.5.2 5 2.6 5 2.6.1 5 2.6.2 5 2.6.3 5 2.6.4 5 2.6.5 6 2.7 6 2.7.1 6 2.7.2 6 2.7.3 6 2.7.4
More information4 100g
100g 10 20 30 40 50 60 70 80 4 5 7 9 12 15 19 24 60 100 10 80 100 20 10 5 20 195 20-1- 60 60 15 100 60 100 15 15 15 100 15 15 60 100 10 60 100 100 15 10 10 60 100 15 10 15 10 5-2- 80 80 24 100 80 100 24
More information70% ADCA 28% SCA6 30% MJD 30% DRPLA 13% 20% SCA1 4% SCA2 3% RCA 2% 537 25 T2 C3 C6) LCL MRI OB ph3 ph9 60/40/20mg/ 1000mg/ 3 500mg/ 6 1000mg/ 3 6/ 2 1 2 3 50 25 0 75 100 % 100 33 67 75 80
More informationMNT MNT CVD MNT 1) 2) 3) 4) MNT 1) 1 2 2) MNT MNT MNT MNT 1 1 2 1 % HbA1C 2
2008 American Diabetes Association, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008 Jan; 31 Suppl 1: S61-S78.
More informationMicrosoft Word - 14_LCMS_アクリルアミド
3--2-3-Iodo-2-propynyl butylcarbamate (IPBC) Carbamic acid, butyl-, 3-iodo-2-propynyl ester Iodocarb CAS 55406-53-6 C 8 H 12 NO 2 I C (g/cm 3 ) (mmhg) log P ow 281.09 (280.9910) 64 68 1.51 1.57 (20 C)
More informationI PD-I-3 VA ICD 2006 NYHA ~ LVEF 35% a ICD SCD-HeFT ICD MADIT- ICD a CABG-Patch ICD EF b MADITø MADIT- MUSTT EPS EPS 19 EPS 5/19 VA PD-I-4 Holter LP f
J Arrhythmia Vol 23 (Suppl) 2007 PD-I-1 OACIS 95% 6.4 (1.5 27.8 4.3 (1.0 18.5), 0.2 (0.05 0.93), respectively MADIT LVEF 30% 192 2.0 12.4% 24 3.1% MADIT 12.1% p=.001), ICD direct PCI OACIS (Osaka Acute
More information